The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

被引：0
|
作者：
Wijaya, Agustinus [1 ]
Bo, Jiang T. [1 ]
Jun, He [2 ]
Ping, Jiang W. [1 ]
Bin, Jiang [1 ]
Jie, Chen H. [2 ]
Wen, Yang B. [1 ]
Zhu, Xu M. [1 ]
Cheng, Qiu Q. [2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Dept Cardiovasc Dis, Suzhou, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Haematol, Suzhou, Jiangsu, Peoples R China
来源：
MEDICAL JOURNAL OF INDONESIA | 2012年 / 21卷 / 02期
关键词：
CYP2C9; pharmacogenetic algorithm; VKORC1; warfarin;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population. Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype ( according to www. warfarindosing. org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0. Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants. Conclusion: There is no significant difference between pharmacogenetic algorithm (www. warfarindosing. org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose.
引用
收藏
页码：108 / 112
页数：5
相关论文
共 50 条
  • [11] Effect of CYP2C9 and VKORC1 genetic polymorphism on Warfarin dose requirement
    Ashavaid, T. F.
    Ponde, C. K.
    Raghavan, R.
    Kapadia, F. N.
    Shah, S. A.
    Natarajan, S.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 507 - 508
  • [12] Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin
    Fung, Erik
    Patsopoulos, Nikolaos A.
    Belknap, Steven M.
    O'Rourke, Daniel J.
    Robb, John F.
    Anderson, Jeffrey L.
    Shworak, Nicholas W.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08) : 893 - 904
  • [13] Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population
    Gaikwad, Tejasvita
    Ghosh, Kanjaksha
    Kulkarni, Bipin
    Kulkarni, Vrinda
    Ross, Cecil
    Shetty, Shrimati
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 710 (1-3) : 80 - 84
  • [14] Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population
    Giri, Anil K.
    Khan, Nazir M.
    Grover, Sandeep
    Kaur, Ismeet
    Basu, Analabha
    Tandon, Nikhil
    Scaria, Vinod
    Kukreti, Ritushree
    Brahmachari, Samir K.
    Bharadwaj, Dwaipayan
    PHARMACOGENOMICS, 2014, 15 (10) : 1337 - 1354
  • [15] Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients
    Ye, Changqing
    Jin, Haiqiang
    Zhang, Rui
    Sun, Yongan
    Wang, Zhaoxia
    Sun, Weiping
    Sun, Wei
    Peng, Qing
    Liu, Ran
    Huang, Yining
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2014, 42 (01) : 67 - 76
  • [16] Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients
    Zhang, Suli
    Zhao, Mingzhe
    Zhong, Shilong
    Niu, Jiamin
    Zhou, Lijuan
    Zhu, Bin
    Su, Haili
    Cao, Wei
    Xing, Qinghe
    Yan, Hongli
    Han, Xia
    Fu, Qihua
    Li, Qiang
    Chen, Luan
    Yang, Fan
    Zhang, Na
    Wu, Hao
    He, Lin
    Qin, Shengying
    PHARMACOGENETICS AND GENOMICS, 2024, 34 (04) : 105 - 116
  • [17] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
  • [18] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [19] VKORC1 and CYP2C9 Genotypes are Predictors of Warfarin-Related Outcomes in Children
    Shaw, Kaitlyn
    Amstutz, Ursula
    Hildebrand, Claudette
    Rassekh, S. Rod
    Hosking, Martin
    Neville, Kathleen
    Leeder, J. Steven
    Hayden, Michael R.
    Ross, Colin J.
    Carleton, Bruce C.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 1055 - 1062
  • [20] Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping
    Maurice, Carleta B.
    Barua, Pankaj K.
    Simses, Diane
    Smith, Penny
    Howe, John G.
    Stack, Gary
    CLINICA CHIMICA ACTA, 2010, 411 (13-14) : 947 - 954
12345